NASDAQ: CTYCity Therapeutics Inc Stock
$20.83-0.63 (-2.94%)
Updated Oct 20, 2026
CTY Price
$20.83
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$20.01
52 Week High
$23.88
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.64
Operating Cash Flow
N/A
Beta
-14.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTY Overview
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTY
Ranked#136 of 457
Ranked#136 of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.76 | A | |
| $10.46 | A | |
| $124.37 | A |
Be the first to know about important CTY news, forecast changes, insider trades & much more!
CTY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTY's short-term assets ($175.69M) exceed its short-term liabilities ($64.76M)
Short-term Liabilities Financials
CTY's short-term assets ($175.69M) exceed its long-term liabilities ($19.52M)
Long-term Liabilities Financials
CTY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more CTY due diligence checks available for Premium users.
Valuation
CTY's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$208.6M
Liabilities
$84.3M
Debt to equity
-0.64
CTY's short-term assets ($175.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTY's short-term assets ($175.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
City Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.